- Home
- FORA vs ADAG Comparison
FORA vs ADAG Comparison
Compare FORA & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- ADAG
- Stock Information
- Founded
- FORA 2014
- ADAG 2011
- Country
- FORA United States
- ADAG China
- Employees
- FORA N/A
- ADAG N/A
- Industry
- FORA Computer Software: Prepackaged Software
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- ADAG Health Care
- Exchange
- FORA Nasdaq
- ADAG Nasdaq
- Market Cap
- FORA 64.0M
- ADAG 76.3M
- IPO Year
- FORA N/A
- ADAG 2021
- Fundamental
- Price
- FORA $2.15
- ADAG $1.90
- Analyst Decision
- FORA Strong Buy
- ADAG Strong Buy
- Analyst Count
- FORA 1
- ADAG 1
- Target Price
- FORA $5.00
- ADAG $8.00
- AVG Volume (30 Days)
- FORA 7.7K
- ADAG 75.4K
- Earning Date
- FORA 08-13-2025
- ADAG 07-24-2025
- Dividend Yield
- FORA N/A
- ADAG N/A
- EPS Growth
- FORA N/A
- ADAG N/A
- EPS
- FORA N/A
- ADAG N/A
- Revenue
- FORA $22,332,001.00
- ADAG $103,204.00
- Revenue This Year
- FORA $13.31
- ADAG $6,488.89
- Revenue Next Year
- FORA $43.65
- ADAG $57.50
- P/E Ratio
- FORA N/A
- ADAG N/A
- Revenue Growth
- FORA 5.22
- ADAG N/A
- 52 Week Low
- FORA $1.85
- ADAG $1.33
- 52 Week High
- FORA $4.03
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- FORA 56.15
- ADAG 52.47
- Support Level
- FORA $1.95
- ADAG $1.73
- Resistance Level
- FORA $2.09
- ADAG $2.02
- Average True Range (ATR)
- FORA 0.11
- ADAG 0.15
- MACD
- FORA 0.01
- ADAG -0.01
- Stochastic Oscillator
- FORA 66.67
- ADAG 42.50
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.